TRIBVN Healthcare announces the creation of a scientific and medical board to guide the development of its imaging and artificial intelligence projects in histopathology. Its purpose is to guide the company in the scientific and technological choices implemented and to ensure that the solutions are well suited to the needs of physicians and patients. This is particularly critical in the development of artificial intelligence algorithms for enhanced diagnosis.
The scientific and medical board is composed of independent scientific researchers and medical pathologists. Francesco Ciompi, Assistant Professor and researcher at the Radboud University Medical Center, specialist in AI for image analysis in pathology, chairs this board. He works closely with the TRIBVN Healthcare executive committee, especially Saima Ben Hadj, AI and Computer Vision Director. Their collaboration allows to determine the best algorithmic approaches, to implement innovative strategies and to enable TRIBVN Healthcare to be a leading and recognized AI actor in pathology.
Francesco Ciompi specifies “I am pleased to join TRIBVN Healthcare in its scientific reflection, particularly on the theme of AI & Pathology. It is from academic and industrial cooperation that the solutions and products that will be used routinely in the future will emerge. I began my role as Chair of the TRIBVN Computational Pathology Scientific Board a few months ago, and since then I have been collaborating with the TRIBVN scientific team on development of AI-based computational pathology solutions . TRIBVN Healthcare is already serving a large number of pathology laboratories for clinical diagnostic, research and teaching, as well as pharma & biotech, making it one of the actors who can reach pathologists and bring innovation with AI-based solutions”
Professors Isabelle Salmon and Jean-François Fléjou, medical pathologists, respectively at the Erasme Hospital – ULB in Brussels and at Saint-Antoine, AP-HP – Sorbonne University in Paris, bring their expertise in pathology and ensure the medical coherence of both product and algorithmic developments. They contribute to the evaluation and validation of the medical benefit of the solutions for physicians and patients, to the understanding and interpretation of medical data, and to the analysis of scientific trends.
Jean-François Pomerol concludes: “The creation of this scientific and medical board is a huge step forward for TRIBVN Healthcare in its desire to develop solutions at the cutting edge of scientific and engineering innovation for the benefit of our clients. By providing vision and expertise, the board will enable us to continue to be one of the leading actors in the field of digital transformation of cancer diagnosis with a major impact on patient care.”
About TRIBVN Healthcare:
TRIBVN Healthcare develops software solutions for digital pathology. Innovative and validated, they allow the management, analysis and sharing of cellular images both for diagnostic laboratories and pharmaceutical & biotech manufacturers. In the field of image analysis, our solutions are based on the latest innovations in terms of artificial intelligence, notably deep and machine learning algorithms. These tools support physicians and researchers in their diagnostic decision-making and scientific evaluation for the sake of patients. In the field of sharing, our solutions implement full web tools to support our customers in their telepathology, teaching or multi-centric clinical validation activities.
Media contact: Pauline Baldo – 01 55 58 05 35 – email@example.com